A Phase 2 Study of AZD2171 in Progressive Unresectable, Recurrent or Metastatic Renal Cell Carcinoma (RCC)

Trial Profile

A Phase 2 Study of AZD2171 in Progressive Unresectable, Recurrent or Metastatic Renal Cell Carcinoma (RCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs Cediranib (Primary)
  • Indications Renal cell carcinoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Sep 2012 Planned end date changed from 1 Dec 2006 to 1 May 2013 as reported by ClinicalTrials.gov record.
    • 13 Oct 2009 Planned number of patients changed from 12 to 37 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top